title: [The use of triptan in ambulatory medicine in Midi-Pyrénées Region: clinical and pharmacological contra-indications and drug abuse].
abstract: OBJECTIVE
  Evaluate triptan prescriptions in ambulatory medicine.
  
  
  METHODS
  Collection of medical data from 301 patients treated with triptans reimbursed by the French National Health Fund in the region of Midi-Pyrenees.
  
  
  RESULTS
  Ninety-five per cent of selected patients suffered from migraine condition according to the International Headache Society diagnosis criteria [Confidence interval (CI) 95%: 93-98]. Co-morbidity factors contra-indicating triptan therapy were present in 6% of patients (CI 95%: 3-9). 2% of patients were prescribed other medicinal products contra-indicated with their triptan therapy (CI 95%: 0-4). Twenty-six per cent of patients were taking triptan medicines more than 8 times per month over a period of three months (CI 95%: 21-31) and 8% were taking this treatment more than 12 times per month (CI 95%: 5-1 I). Eleven per cent kept written information of their migraine crises (CI 95%: 7-15). Thirty-nine per cent benefited from dedicated prophylactic treatments (CI 95%: 33-45).
  
  
  CONCLUSIONS
  In a context of sustained increase in prescriptions of migraine treatments, it appears necessary to remain cautious about clinical and pharmacological contra-indications. Prevention of abuse of medicines is based on a better use of crises agendas and introduction of prophylactic therapies.
authors.affiliation: Direction Régionale du Service Médical de la région Midi-Pyrénées, CNAMTS, Toulouse, France. henri.roussel@ersm-midipyr.cnamts.fr
authors.forename: Henri
authors.initials: H
authors.lastname: Roussel
authors.forename: Geneviève
authors.initials: G
authors.lastname: Lo Re
authors.forename: Christian
authors.initials: C
authors.lastname: Honorat
authors.forename: Michèle
authors.initials: M
authors.lastname: Alonso
authors.forename: Vincent
authors.initials: V
authors.lastname: Sciortino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology; D014363:Tryptamines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014363:Tryptamines